Loading
Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies.
Reinhard Dummer was principal investigator of COLUMBUS, which established encorafenib plus binimetinib in BRAF-mutant melanoma, and led the first randomised neoadjuvant trial of the oncolytic virus talimogene laherparepvec. He has led ESMO melanoma guidelines and trials in cutaneous T-cell lymphoma and Merkel cell carcinoma, and heads the skin cancer centre at University Hospital Zurich.
Shares COLUMBUS, Encorafenib, BRAF, Melanoma and the tag melanoma.
Shares Melanoma and the tags melanoma, targeted-therapy.
Shares Talimogene laherparepvec, Merkel cell carcinoma, Oncolytic viruses, Melanoma and the tag melanoma.
Shares BRAF, Melanoma, Small-molecule kinase inhibitors and the tag melanoma.
Shares Encorafenib, BRAF, Small-molecule kinase inhibitors and the tag targeted-therapy.
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma.
Shares Merkel cell carcinoma, Melanoma and the tag melanoma.
Shares BRAF, Melanoma, Small-molecule kinase inhibitors and the tag melanoma.